Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1018448-65-1
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of ado-trastuzumab during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] However, ado-trastuzumab emtansine also contains DM1, which is a small-molecule toxin that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends avoiding breastfeeding during and for 7 months following ado-trastuzumab emtansine therapy.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Ado-Trastuzumab Emtansine
CAS Registry Number
1018448-65-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Trastuzumab Emtansine.[Drugs and Lactation Database (...]Review Trastuzumab Emtansine.. Drugs and Lactation Database (LactMed®). 2006
- Review Trastuzumab.[Drugs and Lactation Database (...]Review Trastuzumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Mirvetuximab Soravtansine.[Drugs and Lactation Database (...]Review Mirvetuximab Soravtansine.. Drugs and Lactation Database (LactMed®). 2006
- Review Brentuximab Vedotin.[Drugs and Lactation Database (...]Review Brentuximab Vedotin.. Drugs and Lactation Database (LactMed®). 2006
- Review Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.[Ann Pharmacother. 2014]Review Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ann Pharmacother. 2014 Nov; 48(11):1484-93. Epub 2014 Jul 31.
- Ado-Trastuzumab Emtansine - Drugs and Lactation Database (LactMed®)Ado-Trastuzumab Emtansine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...